KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Assets (2016 - 2025)

Alnylam Pharmaceuticals' Non-Current Assets history spans 17 years, with the latest figure at $915.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 3.07% year-over-year to $915.7 million; the TTM value through Dec 2025 reached $3.7 billion, up 6.22%, while the annual FY2025 figure was $915.7 million, 3.07% down from the prior year.
  • Non-Current Assets reached $915.7 million in Q4 2025 per ALNY's latest filing, up from $898.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $945.6 million in Q1 2025 to a low of $784.3 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $859.1 million, with a median of $850.3 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: plummeted 35.39% in 2021, then increased 13.13% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $834.7 million in 2021, then rose by 2.32% to $854.1 million in 2022, then fell by 0.81% to $847.2 million in 2023, then increased by 11.51% to $944.7 million in 2024, then fell by 3.07% to $915.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Non-Current Assets are $915.7 million (Q4 2025), $898.9 million (Q3 2025), and $922.3 million (Q2 2025).